Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib and lenvatinib for differentiated TC, vandetanib and cabozantinib for medullary TC.  Others TKIs such as axitinib, pazopanib, sunitinib, have been tested within phase II trials.  The toxicity burden associated to TKIs is not negligible. 
TKI
Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib and lenvatinib for differentiated TC, vandetanib and cabozantinib for medullary TC.  Others TKIs such as axitinib, pazopanib, sunitinib, have been tested within phase II trials.  The toxicity burden associated to TKIs is not negligible. 
TKIs
Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib and lenvatinib for differentiated TC, vandetanib and cabozantinib for medullary TC.  Others TKIs such as axitinib, pazopanib, sunitinib, have been tested within phase II trials.  The toxicity burden associated to TKIs is not negligible. 
TKIs
Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib and lenvatinib for differentiated TC, vandetanib and cabozantinib for medullary TC.  Others TKIs such as axitinib, pazopanib, sunitinib, have been tested within phase II trials.  The toxicity burden associated to TKIs is not negligible. 
TKIs
Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib and lenvatinib for differentiated TC, vandetanib and cabozantinib for medullary TC.  Others TKIs such as axitinib, pazopanib, sunitinib, have been tested within phase II trials.  The toxicity burden associated to TKIs is not negligible. 
TKIs